An unknown buyer agreed to acquire 38.7% stake in Korea Stem Cell Bank Co., Ltd. from SAMSUNG PHARM. Co., LTD. (KOSE:A001360) for KRW 10 billion on December 30, 2020. SAMSUNG PHARM. Co., LTD. will sell 5.95 million shares of Korea Stem Cell Bank. KRW 1.01 billion was deposited on the date of trading contract of first contract, KRW 200 million on the date of trading contract of second contract and balance KRW 8.8 billion to be deposited on June 30, 2021. SAMSUNG PHARM. Co., LTD. will own 1.2 million shares after completion of the transaction. Korea Stem Cell Bank reported total assets of KRW 79.2 billion, net loss of KRW 16.4 billion, revenue of KRW 1.9 billion and total common equity of KRW 30 billion in previous year. Transaction is expected to close on March 31, 2021. As of March 31, 2021, the transaction is expected to close on June 30, 2021.